<DOC>
	<DOCNO>NCT00982488</DOCNO>
	<brief_summary>This study assess long-term safety tolerability dasatinib administer patient chronic myelogenous leukemia Philadelphia chromosome positive acute lymphoblastic leukemia experience clinical benefit treatment dasatinib imatinib previous protocol .</brief_summary>
	<brief_title>Long-term Safety Dasatinib Patients With Chronic Myelogenous Leukemia Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Key Inclusion Criteria Signed write informed consent Received treatment protocol CA180005 , CA180006 , CA180013 , CA180015 CA180017 , CA180039 Received clinical benefit dasatinib imatinib ( study CA180017 ) opinion Investigator Men woman , age 18 old Key Exclusion Criteria A serious uncontrolled medical disorder active infection would impair ability patient receive protocol therapy Dementia alter mental status would prohibit understanding rendering informed consent Patients currently take drug , include limited quinidine , procainamide , disopyramide , amiodarone , sotalol , ibutilide , dofetilide , erythromycins , clarithromycin , chlorpromazine , haloperidol , mesoridazine , thioridazine , pimozide , ziprasidone , cisapride , bepridil , droperidol , methadone , arsenic , chloroquine , domperidone , halofantrine , levomethadyl , pentamidine , sparfloxacin , lidoflazine , generally accept risk cause Torsades de Pointes Patients take medication know potent CYP3A4 inhibitor ( ketoconazole , ritonavir ) inducer ( rifampin , efavirenz )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>